Glutaredoxin-1 Deficiency Causes Fatty Liver and Dyslipidemia by Inhibiting Sirtuin-1
Open accessThe DOI matches its Crossref record; 11 of the 11 references it cites were found in a registry or an index.
Abstract
Aims: Nonalcoholic fatty liver (NAFL) is a common liver disease associated with metabolic syndrome, obesity, and diabetes that is rising in prevalence worldwide. Various molecular perturbations of key regulators and enzymes in hepatic lipid metabolism cause NAFL. However, redox regulation through glutathione (GSH) adducts in NAFL remains largely elusive. Glutaredoxin-1 (Glrx) is a small thioltransferase that removes protein GSH adducts without having direct antioxidant properties. The liver contains abundant Glrx but its metabolic function is unknown. Results: Here we report that normal diet-fed Glrx-deficient mice ( Glrx −/− ) spontaneously develop obesity, hyperlipidemia, and hepatic steatosis by 8 months of age. Adenoviral Glrx repletion in the liver of Glrx −/− mice corrected lipid metabolism. Glrx −/− mice exhibited decreased sirtuin-1 (SirT1) activity that leads to hyperacetylation and activation of SREBP-1 and upregulation of key hepatic enzymes involved in lipid synthesis. We found that GSH adducts inhibited SirT1 activity in Glrx −/− mice. Hepatic expression of nonoxidizable cysteine mutant SirT1 corrected hepatic lipids in Glrx −/− mice. Wild-type mice fed high-fat diet develop metabolic syndrome, diabetes, and NAFL within several months. Glrx deficiency accelerated high-fat-induced NAFL and progression to steatohepatitis, manifested by hepatic damage and inflammation. Innovation: These data suggest an essential role of hepatic Glrx in regulating SirT1, which controls protein glutathione adducts in the pathogenesis of hepatic steatosis. Conclusion: We provide a novel redox-dependent mechanism for regulation of hepatic lipid metabolism, and propose that upregulation of hepatic Glrx may be a beneficial strategy for NAFL. Antioxid. Redox Signal. 27, 313–327.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Human Fatty Liver Disease: Old Questions and New Insights
Cohen, J. C., Horton, J. D., & Hobbs, H. H. (2011) · Science · doi:10.1126/science.1204265 · Cited by 2,089
Risk of Cardiovascular Disease in Patients with Nonalcoholic Fatty Liver Disease
Targher, G., Day, C. P., & Bonora, E. (2010) · New England Journal of Medicine · doi:10.1056/nejmra0912063 · Cited by 1,907 · cited 2×
“Clinically, NAFL is strongly associated with metabolic syndrome, obesity, type-2 diabetes, and dyslipidemia (2, 52, 53, 69).”
BackgroundDefective lipolysis and altered energy metabolism in mice lacking adipose triglyceride lipase
Haemmerle, G., Lass, A., Zimmermann, R., Gorkiewicz, G., Meyer, C., Rozman, J., Heldmaier, G., Maier, R., Theussl, C., Eder, S., et al. (2006) · Science · doi:10.1126/science.1123965 · Cited by 1,375 · cited 1×
“However, diminished mitochondrial lipid uptake by inhibition of the long chain fatty acid transporter Cpt1a (6) or attenuated hydrolysis of tryglycerides by adipose triglyceride lipase also causes hepatic steatosis (28, 29).”
BackgroundMetabolic control of muscle mitochondrial function and fatty acid oxidation through SIRT1/PGC‐1α
Gerhart‐Hines, Z., Rodgers, J. T., Bare, O., Lerin, C., Kim, S., Mostoslavsky, R., Alt, F. W., Wu, Z., & Puigserver, P. (2007) · The EMBO Journal · doi:10.1038/sj.emboj.7601633 · Cited by 1,294
SIRT1 Regulates Hepatocyte Lipid Metabolism through Activating AMP-activated Protein Kinase
Hou, X., Xu, S., Maitland-Toolan, K. A., Sato, K., Jiang, B., Ido, Y., Lan, F., Walsh, K., Wierzbicki, M., Verbeuren, T. J., et al. (2008) · Journal of Biological Chemistry · doi:10.1074/jbc.m802187200 · Cited by 778 · cited 1×
“Activation or overexpression of SirT1 can alleviate diet-induced NAFL (35, 46, 56) through downregulation of SREBP1 (56).”
BackgroundSelf-citationMouse models in non‐alcoholic fatty liver disease and steatohepatitis research
Anstee, Q. M., & Goldin, R. D. (2006) · International Journal of Experimental Pathology · doi:10.1111/j.0959-9673.2006.00465.x · Cited by 714
The plasma lipidomic signature of nonalcoholic steatohepatitis
Puri, P., Wiest, M. M., Cheung, O., Mirshahi, F., Sargeant, C., Min, H., Contos, M. J., Sterling, R. K., Fuchs, M., Zhou, H., et al. (2009) · Hepatology · doi:10.1002/hep.23229 · Cited by 655 · cited 1×
“Because plasma cholesterol was elevated in Glrx mice, we measured hepatic-free cholesterol (12, 49, 62) and expression of enzymes involved in the classic (cytoplasmic) or ‘‘alternative’’ (acidic) mitochondrial pathway of bile acid formation (27, 55).”
BackgroundCalorie restriction extends yeast life span by lowering the level of NADH
Lin, S.-J., Ford, E., Haigis, M., Liszt, G., & Guarente, L. (2004) · Genes & Development · doi:10.1101/gad.1164804 · Cited by 632
Enhanced free cholesterol, SREBP-2 and StAR expression in human NASH
Caballero, F., Fernández, A., De Lacy, A. M., Fernández-Checa, J. C., Caballería, J., & García-Ruiz, C. (2009) · Journal of Hepatology · doi:10.1016/j.jhep.2008.12.016 · Cited by 368 · cited 2×
“Because plasma cholesterol was elevated in Glrx mice, we measured hepatic-free cholesterol (12, 49, 62) and expression of enzymes involved in the classic (cytoplasmic) or ‘‘alternative’’ (acidic) mitochondrial pathway of bile acid formation (27, 55).”
BackgroundWalker, A. K., Yang, F., Jiang, K., Ji, J.-Y., Watts, J. L., Purushotham, A., Boss, O., Hirsch, M. L., Ribich, S., Smith, J. J., et al. (2010) · Genes & Development · doi:10.1101/gad.1901210 · Cited by 357 · cited 1×
“Conversely, hepatocyte-specific deletion of SirT1 upregulated SREBPs, hydroxy-methylglutaryl-CoA reductase, fatty acid synthase, acyl-CoA desaturase, and induced weight gain and hepatic steatosis in mice (46, 73).”
Background
Cited by
Targeting protein modifications in metabolic diseases: molecular mechanisms and targeted therapies
Wu, X., Xu, M., Geng, M., Chen, S., Little, P. J., Xu, S., & Weng, J. (2023) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-023-01439-y · Cited by 272
Production of adeno-associated virus vectors for in vitro and in vivo applications
Kimura, T., Ferran, B., Tsukahara, Y., Shang, Q., Desai, S., Fedoce, A., Pimentel, D. R., Luptak, I., Adachi, T., Ido, Y., et al. (2019) · Scientific Reports · doi:10.1038/s41598-019-49624-w · Cited by 155
Self-citationNovel Role of the SIRT1 in Endocrine and Metabolic Diseases
Lu, C., Zhao, H., Liu, Y., Yang, Z., Yao, H., Liu, T., Gou, T., Wang, L., Zhang, J., Tian, Y., et al. (2023) · International Journal of Biological Sciences · doi:10.7150/ijbs.78654 · Cited by 160
Role of Glutaredoxin-1 and Glutathionylation in Cardiovascular Diseases
Burns, M., Rizvi, S. H. M., Tsukahara, Y., Pimentel, D. R., Luptak, I., Hamburg, N. M., Matsui, R., & Bachschmid, M. M. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21186803 · Cited by 36
Self-citation
Metadata
- Authors
- Shao, D., Han, J., Hou, X., Fry, J., Behring, J. B., Seta, F., Long, M. T., Roy, H. K., Cohen, R. A., Matsui, R., & Bachschmid, M. M.
- Venue
- Antioxidants & Redox Signaling
- Publisher
- SAGE Publications
- Published
- 2017-08
- Volume
- 27
- Issue
- 6
- Pages
- 313-327
- ISSN
- 1523-0864 (ISSN-L)
- 1557-7716
- OpenAlex
- W2561069382
- Cited by
- 55
- References
- 11
- FWCI
- 2.18
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.